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Abstract
Retinal dystrophies (RD) constitute a group of blinding diseases that are characterized by
clinical variability and pronounced genetic heterogeneity. The different nonsyndromic and
syndromic forms of RD can be attributed to mutations in more than 200 genes. Conse-
quently, next generation sequencing (NGS) technologies are among the most promising
approaches to identify mutations in RD. We screened a large cohort of patients comprising
89 independent cases and families with various subforms of RD applying different NGS
platforms. While mutation screening in 50 cases was performed using a RD gene capture
panel, 47 cases were analyzed using whole exome sequencing. One family was analyzed
using whole genome sequencing. A detection rate of 61% was achieved including muta-
tions in 34 known and two novel RD genes. A total of 69 distinct mutations were identified,
including 39 novel mutations. Notably, genetic findings in several families were not consis-
tent with the initial clinical diagnosis. Clinical reassessment resulted in refinement of the
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clinical diagnosis in some of these families and confirmed the broad clinical spectrum asso-
ciated with mutations in RD genes.
Introduction
Retinal dystrophies (RD) are among the disorders with the highest level of heterogeneity. This
includes genetic heterogeneity, allelic heterogeneity as well as clinical heterogeneity. Molecular
genetic studies in the last two decades revealed ~225 genes that are mutated in one or more of
the various clinical subtypes of RD (https://sph.uth.edu/retnet/). Some of the clinical subtypes
of RD can be caused by mutations in up to 60 different genes, e.g. in retinitis pigmentosa (RP).
Adding to the genetic complexity there is considerable variation in clinical expression and
overlap of symptoms of single disease entities, all of which may hamper making an exact
clinical diagnosis. These obstacles have also practical implications for molecular diagnostics.
Because it is difficult to predict the gene likely to be mutated, a gene-by-gene screening
approach in RD patients is neither time- nor cost-efficient. On the other hand, establishing a
molecular diagnosis is important for several reasons. It is vital for determining the recurrence
risk for future children and therefore provides the basis for accurate genetic counseling. In
many instances, it will also help to predict the clinical course, which is of central importance
for the patients to plan and organize their professional and social lives. There is no effective
cure for RD, however, ongoing clinical trials applying gene-replacement therapy approaches
for several forms of RD have raised new hopes. Since these approaches require the identifica-
tion of the causative mutation, the genetic diagnosis is an essential prerequisite.
The identification of the genetic defect in RD patients has been accelerated by the introduc-
tion of next-generation-sequencing technologies (NGS). Within the field of NGS platforms,
the targeted capture of known disease genes (“disease panels”) has been proven superior in
terms of coverage compared with whole exome sequencing (WES), especially for previous gen-
erations of exome capture reagents [1]. Exome capture kits of newer generations, however,
show an improved performance and also offer the possibility to discover novel genes. On the
other hand, neither conventional “disease panels” nor WES cover non-coding regions. Whole
genome sequencing (WGS), besides its ability to sequence non-coding regions of the genome,
has also been shown to outperformWES in the coding regions [1], but involves higher storage
and analysis costs and is still challenging in terms of bioinformatic analysis.
In this study, we used a retinal capture panel, WES, and in one case WGS, to analyze—in a
research context—89 unrelated cases with different forms of RD. Our results have important
implications for the design and analysis strategy of routine genetic diagnostics in RD.
Materials and Methods
Clinical diagnosis and sample collection
The clinical diagnosis of RD was established by ophthalmological and/or electrophysiological
examination in different clinical centers. The majority of patients were examined in the
outpatient clinic for Inherited Retinal Dystrophies at the Centre for Ophthalmology, (Tue-
bingen, Germany). Others were clinically diagnosed at the outpatient clinic for Retinal Dys-
trophies at the University Eye Hospitals in Munich, Freiburg, and Berlin. Several cases were
from Sweden, Denmark, France, Hungary and the USA. Genomic DNA of patients was
extracted from peripheral blood using standard protocols. Samples from all patients and fam-
ily members were recruited in accordance with the principles of the Declaration of Helsinki
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and were obtained with written informed consent accompanying the patients´ samples. The
study was approved by the institutional review board of the Ethics Committee of the Univer-
sity Hospital of Tuebingen.
Except for a few cases most families had two or more affecteds. For the sake of brevity, in
the following, we refer to multiple patients from one family as one case.
Panel sequencing
We used a capture panel of 105 retinal disease genes (RD panel) to analyze 50 cases. Details of
panel design, library preparation, capture sequencing and variant calling have already been
published [2].
Exome sequencing
We performed duo-based WES (two affected family members) in a cohort of 84 RD patients
from 42 families, while in four cases only one exome was performed. For one family, WES was
performed for three affected family members (pedigree LCA70 is depicted in Fig 1). Eight cases
had been previously analyzed by our RD panel. Exomes were enriched using the SureSelect XT
Human All Exon 50 Mb kit, versions 4 or 5 (Agilent Technologies, Santa Clara, CA, USA).
Sequencing was performed on HiSeq 2500 systems (Illumina, San Diego, CA, USA). Reads
were aligned against the human assembly hg19 (GRCh37) using Burrows—Wheeler Aligner
version 0.7.5 [3]. We performed variant calling using SAMtools version 0.1.18 [4], PINDEL
version 0.2.4t [5] and ExomeDepth version 1.0.0 [6]. Subsequently, variants were filtered using
the SAMtools varFilter script and custom scripts. Shortly, only SNVs and indels in coding
regions (nonsense, missense and canonical splice site variants as well as frameshift indels) hav-
ing a potential effect on protein function in silico (assessed using predictions from PolyPhen-2
[http://genetics.bwh.harvard.edu/pph2/], SIFT [http://sift.bii.a-star.edu.sg/] and CADD
[http://cadd.gs.washington.edu/]) were considered. From those, only private variants or those
with a minor allele frequency<1% in a cohort of more than 66000 control individuals (ExAC
Browser [http://exac.broadinstitute.org/]; and 6742 in-house exomes) were kept for subsequent
analyses.
Genome sequencing
One family was analyzed by whole genome sequencing. Details have already been published
[7].
Molecular validation of the candidate variants
All putative mutations identified by exome sequencing were validated using conventional
Sanger sequencing according to the manufacturer´s protocols (3130XL Sequencer, Applied
Biosystems, Weiterstadt, Germany) and tested for co-segregation within kinships.
Validation of the large deletion in the PRPF31 gene was performed in the seven affected and
eleven unaffected members of family ADRP32 using a long-distance PCR assay. To refine the
breakpoint, we used a forward primer located in exon 3 (aagcaagccaaagcttcaga) and a reverse
primer located in exon 14 (cctgtgggttcacaatctcc). For amplification, we applied a long distance
PCR protocol using 80 ng of genomic DNA in a total volume of 25 μl containing 0.2 μM of
each primer, 400 μM of each dNTP, LA Buffer (1X, without MgCl2), 0.5 mMMgCl2, and 2.5 U
TaKaRa LA Taq DNA polymerase (Takara Bio Europe, Saint-Germain-en-Laye, France). Ther-
mal cycling was performed with the following conditions: 1 min at 94°C followed by 14 cycles
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of 10 s at 98°C, 15 s at 55°C and 4 min at 68°C, a further 16 thermal cycles with an increment
of 4 s/cycle for the elongation step, and a final add-on elongation for 10 min at 68°C.
Validation of the large deletion encompassing exons 15–22 of the EYS gene was performed
using two duplex PCRs in the two affected and three unaffected members of family ARRP28.
Due to the large intron sizes, breakpoints were not precisely defined. Briefly, primers were
designed to co-amplify exons 14 and 15 in one PCR reaction, and exons 22 and 23 in another
PCR reaction, respectively.
Screening for deep intronic variants (denoted as V1–V7) in the ABCA4 gene [8] was per-
formed in family CACD25 in which exome sequencing had revealed a single heterozygous mis-
sense mutation in ABCA4. Screening for V1–V7 was performed as described previously [9].
Characterization of the deep intronic mutation in PROM1 in family RCD49 has been
described before [7].
The mutational hot spot exon of RPGR, ORF15, was not accessible by our sequencing
approaches in all cases due to its highly repetitive sequence. For the mutation screening of
ORF15 in unsolved RP families with absence of male-to-male transmission, we used the proto-
col described in Neidhardt et al. [10].
Results and Discussion
Mutation detection rate
The overall mutation detection rate of our study was 61% (54/89). More specifically, causative
mutations were detected in 25 of 50 cases which were analyzed with our custom RD panel
Fig 1. Pedigrees of six families discussed in detail in the manuscript. The arrows indicate the patients in whom NGS was performed. Family number and
disease-causing mutation(s) are noted above each pedigree. The diagnosis of the patient and the genotype for each mutation are listed below each
individual´s symbol. LCA, Leber congenital amaurosis; BBS, Bardet Biedl syndrome; CRD, cone-rod dystrophy; RP, retinitis pigmentosa; ACHM,
achromatopsia; ADOAC, autosomal dominant optic atrophy and cataract.
doi:10.1371/journal.pone.0145951.g001
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(50%). Average coverage was 750 reads per base pair with approximately 55% reads on target.
In all cases but one, samples from additional family members were used to verify segregation of
the sequence variants identified in the index patient.
Of the 25 cases that remained unsolved using our RD panel, eight were selected for subse-
quent analysis applying WES, in addition to a further 39 cases that were selected for direct
WES analyses. Overall, 91 affected members from 47 families were subjected to WES. A total of
1017 Gigabases of data on target genomic regions were generated for the 91 samples with a
mean coverage of the targeted region of 142 fold (minimum mean coverage was 89 fold). Fol-
lowing WES and subsequent analyses of intronic regions in two cases, we were able to identify
pathogenic mutations in 29 cases (Table 1), thereby achieving a detection rate of 62% (29/47).
In cases attributed to autosomal recessive inheritance that showed two heterozygous muta-
tions, compound heterozygosity was confirmed by segregation analysis in all cases except
three in which no DNA samples of additional family members were available. In cases attrib-
uted to autosomal dominant inheritance, co-segregation in two subsequent generations was
confirmed in all cases except two owing to the lack of additional DNA samples. Of note, we did
not observe any de novomutations in our cohort.
A total of 69 distinct mutations were identified, including 39 novel mutations [11–40].
Although we counted them as being solved for the calculation of the total detection rate,
three families of our cohort were only partially solved. All of them are now supposed to segre-
gate two disease entities: two members of family LCA70 had a diagnosis of LCA while one sib-
ling was diagnosed with Bardet Biedl syndrome (Fig 1). Applying WES to all three siblings we
were able to identify a homozygous splice site mutation in BBS9 that was unique for the patient
with Bardet Biedl syndrome. The underlying mutation of the LCA phenotype in the remaining
two siblings could not be identified so far.
One member of family RCD163 was diagnosed with LCA, while two siblings were diagnosed
with cone-rod dystrophy (Fig 1). Using the RD panel, we could show that the patient with LCA
was compound heterozygous for two frameshift mutations in RPGRIP1 while the two other
siblings were only heterozygous for one of the frameshift mutations. We excluded other vari-
ants in the coding regions and canonical splice site mutations of RPGRIP1 in these patients
using conventional Sanger sequencing. Whether they harbor a second disease-causing muta-
tion in the non-coding regions of RPGRIP1, or whether their phenotype is caused by a second
gene, remains unknown.
In family CHRO89, three brothers with a clinical diagnosis of achromatopsia/color vision
deficiency were analyzed with the RD panel (Fig 1). Targeted sequencing revealed that only
two of them harbour a homozygous frameshift mutation in the CNGB3 gene while the third
brother shows two wildtype alleles. The clinical difference between the brothers has already
been noted in a prior clinical report [41]. Follow-up clinical examination showed that the non-
segregating brother has reduced visual acuity and perifoveal depression of cone responses in
the multifocal ERG, however, his color vision is not achromatic, but deuteranopic and he
shows no nystagmus. The underlying mutation of his phenotype remains unclear.
Of note, eight cases that had been mutation-negative upon the analysis with our custom RD
panel were selected for subsequent WES; five cases could be solved. Applying WES to family
ARRP182 we were able to identify a known homozygous missense mutation in the CLN3 gene.
Yet at the time when the RD panel was applied in this case, it was not known that mutations in
CLN3 can cause nonsyndromic RP and therefore the gene was not included in the panel design.
This clearly shows one of the major disadvantages of a panel-based sequencing approach: if a
gene has not been linked to a specific disease at the time of its design, it will escape detection.
In four cases, RCD70, RCD82, RCD285, and ZD345, WES detected mutations in PROM1,
CRX, and ABCA4, respectively. Although these genes had been included in the RD panel
Mutation Detection in RD Patients Using Targeted NGS
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Table 1. RDmutations identified in our cohort.
ID Final diagnosis Gene Genotype cDNA change Protein change Reference Analysis
Dominant inheritance
ADRP1 Retinitis pigmentosa RP1 Heterozygous c.2161del p.G723Efs*15 [a] WES
ADRP18 Retinitis pigmentosa NR2E3 Heterozygous c.166G>A p.G56R [11] Panel
ADRP32 Retinitis pigmentosa PRPF31 Heterozygous Deletion exons 4–13 p.? [12] WES
ADRP236 Retinitis pigmentosa RP1 Heterozygous c.2329dup p.R777Kfs*4 [a] Panel
ADRP298 Retinitis pigmentosa RHO Heterozygous c.874G>A p.A292T [a] Panel
ADRP308 Retinitis pigmentosa RHO Heterozygous c.512C>T p.P171L [13] Panel
BD121 Exudative vitreoretinopathy FZD4 Heterozygous c.664A>G p.W222R [a] WES
CACD7 Retinitis pigmentosa BEST1 Heterozygous c.584C>T p.A195V [14] WES
MB54 Macular dystrophy GUCA1A Heterozygous c.526C>T p.L176F [a] WES
MDS47 Macular dystrophy BEST1 Heterozygous c.728C>T p.A243V [15] WES
MDS234 Macular dystrophy RP1L1 Heterozygous c.133C>T p.R45W [16] Panel
RCD 70 Cone-rod dystrophy CRX Heterozygous c.502del p.E168Sfs*19 [17] Panel+WES
RCD 82 Cone-rod dystrophy PROM1 Heterozygous c.1117C>T p.R373C [18] Panel+WES
RCD512 Cone-rod dystrophy PROM1 Heterozygous c.1117C>T p.R373C [18] Panel
ZD68 Optic atrophy and cataract OPA3 Heterozygous c.308G>C p.R103H [a] WES
ZD218 Macular dystrophy RP1L1 Heterozygous c.133C>T p.R45W [16] Panel
ZD302 Macular dystrophy RP1L1 Heterozygous c.133C>T p.R45W [16] Panel
ZD367 Cone dystrophy CRX Heterozygous c.238G>A p.E80K [19] Panel
ZD396 Cone-rod dystrophy GUCY2D Heterozygous c.2513G>A p.R838H [20] Panel
Recessive inheritance
ARRP17 Retinitis pigmentosa CRB1 Heterozygous c.407G>A p.C136Y [a] WES
Heterozygous c.1465G>T p.E489* [a]
ARRP28 Retinitis pigmentosa EYS Homozygous Deletion exons 15–22 p.? [a] Panel
ARRP50 Retinitis pigmentosa EYS Homozygous c.5927+1G>T p.? [a] Panel
ARRP75 Retinitis pigmentosa PDE6B Homozygous c.1699C>T p.Q567* [21] Panel
ARRP82 Retinitis pigmentosa USH2A Heterozygous c.9433C>T p.L3145F [a] WES
Heterozygous c.13335_13347del13ins4 p.
E4445_S4449delinsDL
[a]
ARRP83 Retinitis pigmentosa TULP1 Homozygous c.1604T>C p.F535S [21] Panel
ARRP138 Retinitis pigmentosa CERKL Homozygous c.1090C>T p.R364* [22] Panel
ARRP142 Retinitis punctata albescens RLBP1 Homozygous c.398del p.P133Qfs*126 [23]§ Panel
ARRP165 Retinitis pigmentosa IQCB1 Homozygous c.1558C>T p.Q520* [a] Panel
ARRP182 Retinitis pigmentosa CLN3 Homozygous c.1213C>T p.R405W [24] Panel+WES
ARRP201 Retinitis pigmentosa CYP4V2 Heterozygous c.283G>A p.G95R [25] WES
Heterozygous c.1198C>T p.R400C [26]
ARRP210 Retinitis pigmentosa IFT140 Heterozygous c.472C>T p.R158W [a] WES
Heterozygous c.1565G>A p.G522E [27]
ARRP230 Retinitis pigmentosa MAK Homozygous c.79G>C p.G27R [28] WES
ARRP255 Retinitis pigmentosa USH2A Heterozygous c.2610C>A p.C870* [29] WES
Heterozygous c.12261G>C p.W4087C [a]
CACD25 Macular dystrophy ABCA4 Heterozygous c.5196+1137G>A$ p.? [8] WES
Heterozygous c.5311G>A p.G1771R [a]
CHRO89 Achromatopsia CNGB3 Homozygous c.1430_1431delinsC p.K477Tfs*17 [a] Panel
CHRO234 Alström syndrome ALMS1 Homozygous c.1043G>A p.W348* [a] WES
CHRO249 Cone-rod dystrophy RAB28 Homozygous c.565G>A p.Q189* [30]§ WES
CHRO391 Bardet Biedl syndrome BBS5 Homozygous c.790G>A p.G264R [a] WES
(Continued)
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design, the disease-causing variants in the four families were only detected by WES. Retrospec-
tive analysis of the panel sequencing data showed insufficient coverage of these regions. Later
versions of the RD panel comprise additional probes and show a significantly improved cover-
age of these regions. Finally, family RCD49 could only be solved after applying WGS, simply
due to the fact that the disease-causing mutation is located deep in an intron of PROM1 and
thereby could not be captured by the panel or by the WES approach.
Comparison with other NGS studies on RD
In the present study, we applied a custom RD panel interrogating 105 RD genes to analyze 50
cases and were able to solve 25 cases. This detection rate of 50% is somewhat lower in
Table 1. (Continued)
ID Final diagnosis Gene Genotype cDNA change Protein change Reference Analysis
CHRO436 Achromatopsia ATF6 Heterozygous c.797dup p.N267* [31]§ WES
Heterozygous c.1110dup p.V371Sfs*3 [31]§
CHRO865 Achromatopsia PDE6C Heterozygous c.88_98del p.V30Gfs*19 [a] WES
Heterozygous c.1205T>A p.V402E [a]
LCA70 Leber congenital amaurosis
and Bardet Biedl syndrome
BBS9 Homozygous c.1693+1G>A p.? [a] WES
MST177 Stargardt disease ABCA4 Heterozygous c.2588G>C p.G863A [32] WES
Heterozygous c.3898C>T p.R1300* [33]
RCD49 Cone-rod dystrophy PROM1 Homozygous c.2077-521A>G p.S684Ifs*21 [7]§ Panel+WES
+WGS
RCD69 Cone-rod dystrophy CDHR1 Heterozygous c.1448A>G p.E483G [a] Panel
Heterozygous c.2522_2528del p.I841Sfs*119 [a]
RCD117 Cone-rod dystrophy CERKL Heterozygous c.356C>T p.G119D [a] Panel
Heterozygous c.715G>A p.R239* [a]
RCD163 Cone-rod dystrophy RPGRIP1 Heterozygous c.630del p.H198Tfs*50 [a] Panel
Heterozygous c.2796dup p.E933* [a]
RCD281 Cone-rod dystrophy TULP1 Heterozygous c.1025G>A p.R342Q [34] Panel
Heterozygous c.1496-6C>A p.? [35]
RCD285 Cone-rod dystrophy PROM1 Heterozygous c.1327dup p.S443Ffs*22 [a] Panel+WES
Heterozygous c.1557C>A p.Y519* [36]
RCD500 Leber congenital amaurosis CEP290 Heterozygous c.4723A>T p.K1575* [37] Panel
Heterozygous c.5254C>T p.R1752W [21]
ZD345 Cone dystrophy ABCA4 Heterozygous c.4139C>T p.P1380L [38] Panel+WES
Heterozygous c.4253+4C>T p.? [39]
ZD410 Cone dystrophy ABCA4 Heterozygous c.1622A>G p.L541P [40] Panel
Heterozygous c.1643C>T p.W548* [a]
X-linked inheritance
ADRP276 Retinitis pigmentosa RPGR Hemizygous c.1245+1G>T p.? [a] Panel
RCD291 Cone-rod dystrophy RPGR Hemizygous c.3011_3012del p.E1004Gfs*74 [a] WES
Simplex cases
LCA89 Leber congenital amaurosis CEP290 Heterozygous c.3310-1_3310delinsAA p.? [a] WES
Heterozygous c.5825A>C p.Q1942P [a]
§Identified in this study but already published;
$not identified by WES but by subsequent screening for this variant;
a, this study.
doi:10.1371/journal.pone.0145951.t001
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comparison with a prior study using the same custom RD panel in a genetic diagnostic context
setting (55% detection rate; [2]) as well as when compared with other studies which also used
panel-based sequencing approaches. Eisenberger and colleagues [21] analyzed 55 genes in a
cohort of 70 patients with RP and 56 patients with LCA and achieved an overall mutation
detection rate of 70%. Other panel-based studies obtained similar results: in a cohort of 82 RP
families from Northern Ireland disease-causing mutations were identified in 60% [42]. Another
study analyzed 179 Chinese families with RD and achieved a detection rate of 55.3% [43]. The
fact that we obtained only a detection rate of 50% in this study might be due to several reasons:
1) our cohort is more diverse concerning clinical phenotypes and inheritance traits; 2) we used
a very early version of the RD panel which had some technical limitations; and 3) our cohort
is somewhat biased since most cases had been extensively pre-screened for mutations in fre-
quently affected genes applying Sanger sequencing and/or APEX arrays.
As for our detection rate of 62% in the cases that were analyzed by WES, a direct compari-
son with other studies is complicated due to differences in both cohort size and composition
regarding clinical phenotypes and inheritance traits. Corton and colleagues used WES to ana-
lyze twelve Spanish families with presumed recessive RD and were able to solve ten of them
[44]. Another study was able to identify disease-causing mutations in four of six Spanish fami-
lies with an initial diagnosis of autosomal dominant RP [45]. A very recent study that analyzed
90 patients from 68 Israeli and Palestinian families with diagnoses of RP and LCA achieved a
detection rate of 49% [46].
Genetic heterogeneity
A total of 69 distinct mutations were identified in our study; 39 of them had not previously
been reported (Tables 1 and 2). Among these novel mutations, 25 were nonsense, frameshift
or splice site mutations presumably leading to functional null alleles while 14 were missense
mutations that were predicted to have a deleterious effect on protein function in silico. Twelve
of the novel missense mutations were absent from the ExAC database and two had a minor
allele frequency of less than 0.00001.
With 36 genes implicated in disease in 54 families, and only few recurrent mutations in the
same gene (Table 3), our observations reaffirm the known genetic heterogeneity of RD in an
outbred European population. Similar genetic heterogeneity was also noted in 126 RP and
LCA patients [21].
Besides the identification of mutations in already known RD genes, WES led to the identi-
fication of two genes that had not previously been associated with RD, demonstrating a
major advantage of WES in a research setting. The extreme genetic heterogeneity in RD usu-
ally makes it very unlikely to identify—in a limited study cohort—more than one family car-
rying mutations in a novel RD gene. However, such initial findings of potential candidates
Table 2. Classification of all identified putative pathogenic mutations.
Novel Previously reported
Missense 14 19
Nonsense 6 6
Splice site 3 2
Small deletions/insertions 14 1
Large deletions 1 1
Deep intronic 1 1
Total 39 (57%) 30 (43%)
doi:10.1371/journal.pone.0145951.t002
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may find a match in databases listing single genetic findings (GeneMatcher; https://
genematcher.org) or within the public domain of large consortia (e.g. the European Retinal
Disease Consortium; http://www.erdc.info/) or will guide targeted screening in larger patient
cohorts. Applying this strategy we were able to identify, or substantiate identification of,
respectively, two novel genes associated with RD in our cohort of 47 families that underwent
WES. In family CHRO249 we identified a homozygous nonsense mutation in RAB28 that
led to the first description of this gene being associated with cone-rod dystrophy [30] and in
family CHRO436 we identified two heterozygous frameshift mutations in the ATF6 gene,
lending further support to our identification of ATF6 as a novel gene for achromatopsia [31].
Replicates of initial findings may still be challenging for novel candidate genes of ultra-rare
disease entities represented by several unsolved cases in our study cohort (e.g. autosomal
dominant vitreoretinochoroidopathy in family BD49 and atrophy of the choroid and
retina in family BD35, presenting with a fundus appearance of gyrate atrophy but without
hyperornithinemia).
Two cases were shown to harbor pathogenic deep intronic mutations: family CACD25 is
compound heterozygous for a missense mutation and a deep intronic mutation in ABCA4 that
affects splicing [8]. Two affected siblings of family RCD49 are homozygous for a deep intronic
mutation in PROM1 that leads to the activation of a cryptic exon [7].
Table 3. Distribution of involved genes in our RD cohort.
Clinical diagnosis Solved cases/total
number of cases
Mutated genes (number of cases)
ar Retinitis pigmentosa 13/14 CERKL (1), CLN3 (1), CRB1 (1), CYP4V2 (1), EYS (2), IFT140 (1), IQCB1 (1), MAK
(1), PDE6B (1), TULP1 (1), USH2A (2)
ad Retinitis pigmentosa 7/19 BEST1 (1), NR2E3 (1), PRPF31 (1), RHO (2), RP1 (2)
X-linked Retinitis pigmentosa 1/1 RPGR (1)
ar Cone-rod dystrophy 7/16 CERKL (1), CDHR1 (1), PROM1 (2), RAB28 (1), RPGRIP1 (1), TULP1 (1)
ad Cone-rod dystrophy 4/5 CRX (1), GUCY2D (1), PROM1 (2)
X-linked Cone-rod dystrophy 1/1 RPGR (1)
ar Cone dystrophy 2/6 ABCA4 (2)
ad Cone dystrophy 1/2 CRX (1)
ar Macular dystrophy 1/2 ABCA4 (1)
ad Macular dystrophy 5/6 BEST1 (1), GUCA1A (1), RP1L1 (3)
Leber congenital amaurosis 2/3 CEP290 (2)
Achromatopsia 3/3 ATF6 (1), CNGB3 (1), PDE6C (1)
Stargardt disease 1/1 ABCA4 (1)
Alström syndrome 1/1 ALMS1 (1)
Bardet Biedl syndrome 2/2 BBS5 (1), BBS9 (1)*
Optic atrophy and cataract 1/1 OPA3 (1)
Exudative vitreoretinopathy 1/1 FZD4 (1)
Retinitis punctata albescens 1/1 RLBP1 (1)
Oligocone trichromacy 0/2 -
ad Vitreoretinochoroidopathy 0/1 -
Gyrate atrophy-like choroidal
atrophy
0/1 -
ar, autosomal recessive; ad, autosomal dominant;
*both Bardet Biedl syndrome and Leber congenital amaurosis are diagnosed in family LCA70.
doi:10.1371/journal.pone.0145951.t003
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Revision of the initial clinical diagnosis
Our cohort included 47 cases attributed to autosomal recessive (53%) and 37 cases attributed
to autosomal dominant inheritance (42%). Two cases were X-linked (2%) and three cases were
isolated (3%). Final diagnoses of participating subjects included RP (34 cases), cone-rod dystro-
phy (23 cases), cone dystrophy (eight cases), macular dystrophy (eight cases), Leber congenital
amaurosis (LCA; three cases), achromatopsia (three cases) and oligocone trichromacy (two
cases). Additional single cases had final diagnoses of retinitis punctata albescens, autosomal
dominant vitreoretinochoroidopathy, atrophy of the choroid and retina resembling gyrate
atrophy but without hyperornithinemia, exudative vitreoretinopathy, optic atrophy, Alström
syndrome, Bardet Biedl syndrome and Stargardt disease.
In several families we observed an inconsistency between expected findings based on the ini-
tial clinical diagnosis and the actual genetic result: family CHRO391, initially diagnosed with
achromatopsia in childhood, was clinically re-examined since the only rare and potentially dis-
ease-causing exonic variants compatible with a model of autosomal recessive inheritance and
shared by both siblings was a novel homozygous missense mutation in BBS5. Clinical re-exam-
ination revealed that the only symptom that could be attributed to Bardet Biedl syndrome is
obesity. Neither polydactyly, renal dysfunction, hypogonadism, nor cognitive impairment was
observed. However, the phenotype of Bardet Biedl syndrome is very variable and it has been
shown that mutations in other BBS genes, like BBS1 and BBS2, can cause mild forms or even
nonsyndromic retinal dystrophy [47–48]. It is therefore likely, that the mutation in BBS5 we
found is the underlying cause of the phenotype in family CHRO391, especially since we did not
find any variants in other genes that were considered pathogenic.
WES also helped to clarify distinct disease causes in family ARRP230: only one of two sisters
initially diagnosed with RP was shown to be homozygous for a known missense mutation in
MAK while the clinical symptoms of her sister, who does not carry the mutation, were shown
to be due to chronic uveitis (Fig 1).
Family ZD68 had an initial diagnosis of cone dystrophy, and as a differential diagnosis optic
atrophy and cataract (Fig 1). Genetic analysis showed that the two siblings harbor a novel mis-
sense mutation in the OPA3 gene, which is implicated in autosomal dominant optic atrophy
and cataract (ADOAC).
Two siblings of family ARRP210 were shown to harbor two heterozygous missense muta-
tions in IFT140 (Fig 1). This gene encodes a member of intraflagellar transport (IFT) proteins
involved in bidirectional protein trafficking along the cilium. Mutations in genes coding for
IFT components have been associated with several ciliopathies. In some instances, mutations
might result in isolated forms of retinal degeneration, as has been shown for IFT172 [49], and
only recently for IFT140 [50]. Prior to the latter publication, mutations in IFT140 had only
been described in patients with Mainzer-Saldino syndrome and Jeune asphyxiating thoracic
dystrophy [27,51]. Both syndromes involve skeletal, renal, hepatic and retinal abnormalities.
Extra-ocular symptoms are not apparent in the two siblings of family ARRP210 but could not
yet be excluded by radiologic and internistic examinations. Nevertheless, our findings might
confirm the recent finding that mutations in IFT140 can result in nonsyndromic RP.
Copy number variation
Copy number variations (CNV) are an important cause of human disease [52]. In RD, patho-
genic CNVs have been described in a number of genes. For instance, deletions of one or more
exons account for a considerable part of the mutation spectrum of USH2A, EYS and PRPF31
(source: HGMD, http://www.biobase-international.com/product/hgmd). The accurate detec-
tion of large heterozygous deletions or duplications in WES data is considered one of the
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pitfalls of the method but is possible when applying suitable algorithms [53]. We used Exome-
Depth [6] to discover CNVs in our data sets and were able to identify a large heterozygous
deletion spanning exons 4–13 of the PRPF31 gene in family ADRP32. In addition to the
computational approach, we manually compared the number of exon reads for known RD
genes in the unsolved cases but were not able to identify additional CNVs.
RPGRORF15
Despite the fact that our bioinformatic pipeline successfully identified a pathogenic deletion in
ORF15 of the RPGR gene in family RCD291, several issues prompted us to screen ORF15 by
conventional Sanger sequencing in unsolved RP families showing no male-to-male transmis-
sion: 1) The high incidence of X-linked RP among families initially classified as dominant [54],
2) the large proportion of ORF15mutations in X-linked RP [55], and 3) the poor coverage of
ORF15 in exome data due to its high repetitive nature. However, we were not able to identify
additional disease-causing mutations in ORF15 in our cohort.
Unsolved cases—possible explanations
Thirty-five cases of our cohort could not be solved so far. Of these, 17 have only been analyzed
by means of our custom RD panel. As discussed above, we used an early version of the RD
panel which did not interrogate several more recently discovered RD-associated genes and also
had some technical limitations. Of the 18 cases that remained unsolved after WES, seven cases
were analyzed using a previous version of the exome capture kit. It has been shown that librar-
ies obtained with the most recent Agilent V5 kit result in 94.57% of the targeted region covered
by at least 20x compared with only 88.75% of the targeted region when the Agilent V4 kit was
used [1]. Yet we did not achieve a higher detection rate in the group of cases that have been
analyzed with V5 compared with those that have been analyzed with V4.
Of note, within the cohort that was analyzed by WES, we were able to solve a significantly
lower fraction of cases with dominant inheritance (9/19) compared to cases with recessive
inheritance (18/24). On average, our variant detection and annotation pipeline identified 100–
150 sequence variants per family with dominant inheritance that were rare, potentially affect-
ing protein function and shared by two affected family members. Even after filtering for retinal
expression, several dozens of variants remained which made prioritization of novel candidate
genes for dominantly inherited RD challenging.
Regardless of the inheritance pattern, it is likely that some causal variants will be structural
or reside within non-coding regions. Genomic analyses for genes involved in retinal degenera-
tion like ABCA4 [8–9], USH2A [56–57] and CEP290 [58] have shown that a probably underes-
timated number of patients harbor deep intronic variants that interfere with splicing. Some
families might therefore be solved by WGS, like performed for family RCD49, in which we
were able to identify a pathogenic deep intronic mutation in PROM1. However, computational
analyses of WGS data sets are challenging and most likely only have prospect for success in
families with multiple affecteds and evidence of linkage to known disease-gene loci.
Lessons from our study
An important factor that might hamper identification of disease-causing mutations is inaccu-
rate or insufficient pedigree information with regard to inheritance, disease entity or disease
status. Although all our cases have been followed clinically for many years, we took into
account the possibility of an imprecise clinical diagnosis or unexpected forms of inheritance
since the wide phenotypic variability of RD with the clinical overlap of symptoms often ham-
pers accurate clinical diagnosis. This obstacle was impressively demonstrated by the fact that
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our molecular findings led to the reclassification of the phenotype in several families. A good
example for inaccurate pedigree information in our cohort is family ARRP230: both affected
sisters had initially been diagnosed with retinitis pigmentosa but only one of them is homozy-
gous for a known missense mutation inMAK. Retrospectively, the other sister was shown to
suffer from chronic uveitis and not from retinitis pigmentosa. If we had only considered over-
lapping variants we would have missed theMAK variant. Moreover, three families in our
cohort were shown to segregate two disease entities. This shows how important it is to analyze
exome data sets with a hypothesis-free approach, especially in RD, with its pronounced clinical
and genetic heterogeneity.
There is an increasing number of reports describing disease-causing mutations in non-cod-
ing sequences in RD families [8,58–61]. However, such reports are mainly based on incidental
findings and there is a lack of a systematic study on the prevalence of such “cryptic”mutations.
In our cohort of 89 unrelated cases, we were able to identify coding mutations in 52 cases while
non-coding mutations were found in two cases, corresponding to 5% of previously unsolved
cases; this confirms the necessity of analysis of regions outside of the coding exons. We there-
fore recommend that in future studies mutation screening should include at least as a second
level screening, the analysis of non-coding regions of known RD disease genes.
In summary, our study confirms the diagnostic value of NGS platforms in the identification
of mutations in a heterogeneous disease like RD. The advantage of WES to discover novel
genes together with its reliable variant calling of coding regions and competitive prices, make it
the technique of choice in the mutation screening of heterogeneous diseases.
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